Clinical trial Recruiting at 1 site Interventional Ages 7 to 21

Brain-computer interface neurofeedback to improve thinking skills after brain injury

Official title: Cognitive Rehabilitation Using Neurofeedback With Brain-computer Interface - CONNECT: A Prospective Randomised Controlled Trial

Run by KK Women's and Children's Hospital · NCT07828496 · Data updated 2026-11-12

Researchers are testing a brain-computer interface neurofeedback program to see if it can improve attention, memory, and executive function in kids and teens who have had a brain injury or epilepsy, compared with standard care.

Quick facts

Study typeInterventional
Ages7 Years to 21 Years
SexAll
Enrollment70 (estimated)
SponsorKK Women's and Children's Hospital
Government
Locations1 site (Singapore)
StatusRecruiting
StartedNovember 1, 2025
Main results expectedFebruary 1, 2028
Study endsJune 30, 2028
Registry record updatedSeptember 18, 2026
Trial IDNCT07828496 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children and adolescents aged 7 to 21 with acquired brain injury (e.g., TBI, stroke, encephalitis, brain tumor) or epilepsy who can participate in neuropsychological assessments and tolerate the neurofeedback sessions.

Probably not a fit

Participants who have contraindications to neurofeedback, cannot cooperate with cognitive assessments, or whose condition is unlikely to respond to the intervention may see no benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study tests a brain-computer interface (BCI) with neurofeedback delivered through 3D game sessions to children and adolescents aged 7 to 21 years who have acquired brain injuries or epilepsy. The study will also enroll a normative group without brain injury to establish baseline EEG measures of attention and relaxation. Key questions are whether EEG markers of sustained, selective, and relaxed attention reflect cognitive impairment after ABI, and whether the BCI-NFT program can improve cognitive and behavioral outcomes compared with standard care. The study uses EEG-derived measures and behavioral assessments to track changes in attention, memory, and executive function. Lead involvement is KK Women’s and Children’s Hospital in Singapore, with no listed collaborators.

Why it matters

Potential benefit: If successful, participants may experience improvements in attention, memory, and executive function, potentially translating to better daily functioning.

How similar studies have gone: Neurofeedback and EEG-based markers have shown promise in related cognitive rehabilitation approaches, but this exact BCI-NFT program in ABI/epilepsy youth is exploratory.

Who can join: the full rules

Show full inclusion / exclusion criteria
Normaitve cohort:

\- Patients with no history of epilepsy

Inclusion Criteria:

* Post acquired brain injury (stroke, encephalitis, brain tumour, traumatic brain injury)
* Epilepsy

Exclusion Criteria:

* History of photosensitive seizures
* Diagnosis of intellectual disability
* Presence of psychotic symptoms
* Diagnosis of attention deficit and hyperactivity disorder
* Diagnosis of autism spectrum disorder
* Children on methylphenidate
* Children who are unable to cooperate with neuropsychological assessment of cognitive function

Where it's running

  • KK Women's and Children's Hospital
    Singapore, Singapore
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.